New leukemia drug suppresses cancer-driving protein more strongly than existing treatments within one week
A more effective and better-tolerated treatment for chronic myeloid leukemia (CML) could improve quality of life for people living with the disease. A new study led by Adelaide University and the South Australian Health and Medical Research Institute (SAHMRI) has provided the first direct evidence that a targeted therapy can rapidly and consistently suppress the molecular signals that drive CML.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
